Q3 25 EPS
$2.47
BEAT +15.67%
Est. $2.14
Q3 25 Revenue
$7.77B
BEAT +4.14%
Est. $7.46B
vs S&P Since Q3 25
-0.2%
TRAILING MARKET
GILD +7.3% vs S&P +7.6%
Market Reaction
Did GILD Beat Earnings? Q3 2025 Results
Gilead Sciences delivered a strong Q3 2025, with non-GAAP diluted EPS of $2.47 clearing the $2.14 consensus by 15.67% and revenue of $7.77 billion beating estimates by 4.14% on 3.0% year-over-year growth. The headline driver was a $400 million royalt… Read more Gilead Sciences delivered a strong Q3 2025, with non-GAAP diluted EPS of $2.47 clearing the $2.14 consensus by 15.67% and revenue of $7.77 billion beating estimates by 4.14% on 3.0% year-over-year growth. The headline driver was a $400 million royalty and contract revenue boost tied to a prior intellectual property sale, though the underlying business showed genuine momentum: the HIV franchise grew 4% to $5.28 billion, anchored by Biktarvy's 6% rise to $3.69 billion, while the liver disease portfolio advanced 12% to $819 million on Livdelzi uptake. Non-GAAP operating margin expanded 729 basis points to 50.5%, underscoring the operating leverage at play. Strategically, Biktarvy patent settlements push generic entry to April 2036, and lenacapavir's strong PrEP approval momentum adds a durable long-term growth layer, much as large-cap pharma peers have leaned on blockbuster franchises to sustain premium valuations. Gilead raised full-year non-GAAP EPS guidance to $8.05-$8.25, reflecting continued confidence in its core portfolio execution.
Key Takeaways
- • Biktarvy sales grew 6% YoY driven by higher demand and favorable inventory dynamics
- • Descovy sales surged 20% YoY on higher demand
- • Livdelzi uptake drove 12% growth in liver disease portfolio
- • Trodelvy sales grew 7% YoY on higher demand
- • Royalty, contract and other revenues increased ~$400M related to a prior IP sale (one-time)
- • Lower acquired IPR&D expenses compared to prior year
- • Higher net unrealized gains on equity investments
GILD YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
GILD Revenue by Segment
With YoY comparisons, source: SEC Filings
GILD Revenue by Geography
With YoY comparisons, source: SEC Filings
“We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer.”
— Daniel O'Day, Q3 2025 Earnings Press Release
GILD Earnings Trends
GILD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GILD EPS Trend
Earnings per share: estimate vs actual
GILD Revenue Trend
Quarterly revenue: estimate vs actual
GILD Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.91 | $2.03 | +6.30% | $6.96B | +0.51% |
| Q4 25 BEAT FY | $1.83 | $1.86 | +1.88% | $7.93B | +3.21% |
| FY Full Year | $8.12 | $8.15 | +0.40% | $29.44B | +0.82% |
| Q3 25 BEAT | $2.14 | $2.47 | +15.67% | $7.77B | +4.14% |
| Q2 25 BEAT | $1.96 | $2.01 | +2.72% | $7.08B | +1.69% |
| Q1 25 BEAT | $1.77 | $1.81 | +2.11% | $6.67B | -2.14% |